Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

ENTO Entero Therapeutics Inc

0,496

0,00 (0,00%)

05 Dez 2024 - Geschlossen

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Entero Therapeutics (NASDAQ:ENTO)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more Entero Therapeutics Charts.

Entero Therapeutics (NASDAQ:ENTO)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Click Here for more Entero Therapeutics Charts.

News Entero Therapeutics Inc

Form 8-K - Current report
Mittwoch 27 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum
Donnerstag 14 November 2024 (3 Wochen vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 13 November 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 13 November 2024 (3 Wochen vor) • Edgar (US Regulatory)

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
Mittwoch 13 November 2024 (3 Wochen vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Montag 21 Oktober 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 10 Oktober 2024 (2 Monate vor) • Edgar (US Regulatory)

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
Dienstag 10 September 2024 (3 Monate vor) • GlobeNewswire Inc.

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
Freitag 23 August 2024 (3 Monate vor) • GlobeNewswire Inc.

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
Mittwoch 31 Juli 2024 (4 Monate vor) • GlobeNewswire Inc.

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
Donnerstag 27 Juni 2024 (5 Monate vor) • GlobeNewswire Inc.

Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
Mittwoch 22 Mai 2024 (6 Monate vor) • GlobeNewswire Inc.

Weitere Entero Therapeutics Inc News-Artikel

Energy Select Sector SPDR

Gold vs US Dollar

Euro vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen